The global biosurgery market was valued at USD 12,995.96 million in 2022. It is projected to reach USD 26,991.2 million by 2031, growing at a CAGR of 6.87% during the forecast period (2023-2031).
Biosurgery, often referred to as maggot debridement therapy or larval therapy, involves sealing surgical incisions and wounds with natural, synthetic, or semi-synthetic materials. It is frequently used to stop excessive bleeding, provide adhesion for sealing wounds or tissues, and mend broken bones and tissues. Biosurgery refers to using biological and synthetic materials during surgery to prevent complications, improve surgical techniques, and address various surgical needs, such as preventing excessive bleeding, lowering the risk of infection, and debridement of the necrotic, slough, devitalized wounds or tissues, and defects. Chronic wounds, including osteomyelitis, leg ulcers, burns, malignant wounds, infected surgical wounds, abscesses, and infected wounds, are treated with biosurgery products. During thoracic, spinal, and cranial surgery, biosurgery equipment also aids in preventing intraoperative air leaks and cerebrospinal fluid preservation leakage.
Biosurgeries have expanded due to technological developments and advances in healthcare facilities worldwide since they have long been considered the most desirable surgical technique. In general surgery, biosurgeries are frequently used as an alternative to traditional open surgery for orthopedic, cardiac, neurological, gynecological, and reconstructive procedures. It is a surgical technique that uses numerous natural and artificial biological components. These items frequently isolate the wound and reduce blood loss by soaking up the fluids and closing the site. Using these medicines during surgical operations minimizes post-operative recovery time and complications related to surgery.
Due to the rising prevalence of several chronic diseases, including cancer, cardiac disorders, gynecological cancers, inflammatory disease, infertility, and several orthopedic diseases, as well as the rising demand for surgical procedures, biosurgeries have seen a spectacular increase in demand over the last few decades in both developing and developed countries. Orthopedic conditions are among the main impetuses for biosurgical techniques encouraging the body's regenerative mechanisms to repair musculoskeletal tissues harmed by trauma or illnesses. The elements above are anticipated throughout the forecast period to drive the biosurgery market. The increased incidence of cancer is also anticipated to fuel market expansion.
The factors anticipated to constrain the industry's growth throughout the projected period include the high procedural expenses and supplemental spending on medical testing, post-surgery clothing, and pharmaceuticals. However, due to the high costs and hazards associated with surgery, only some people are willing to have it done. Risks include a drawn-out recovery period and uncertainty over whether the procedure will be successful. For instance, it is thought that joint replacement surgery has a risk of problems such as infections and implant failure. The total surgical operation cost that the patient is responsible for comprises the initial consultation charge, anesthetic fees, operating room fees, the surgeon's fees, and any aftercare costs. Consequently, each of these problems impedes the biosurgery market's expansion.
Medical device manufacturers must continue to create new items for use by surgeons as the need for more complex surgical operations rises in response to new technologies. Globally, medical technology has advanced at an exponential rate. Global operations help to drive up the sophistication of medical technology innovation rates. Manufacturers are creating products that could form the foundation of new markets to deal with medical technology improvements, and they are also developing technologies that could help the biosurgery industry.
Manufacturers frequently invest time and resources in research to generate discoveries that aid in creating new goods or methods of operation. They seek to enhance the current interests or procedures. These operations fall under the research and development umbrella (R&D). Additionally, increasing government initiatives and clinical trials aim to support and encourage these studies. The increased focus on research and development to create more innovative biosurgery products, as well as ongoing development and healthcare technology developments, are fueling the market's expansion.
Based on product, the global biosurgery market is bifurcated into hemostatic agents, bone-graft substitutes, surgical sealants and adhesives, soft-tissue attachments, adhesion barriers, and staple line reinforcement.
The hemostatic agents' segment is the highest contributor to the market and is estimated to grow at a CAGR of 5.26% during the forecast period. Hemostatic medications are frequently used to help control bleeding because they speed up the body's natural clotting process, which reduces external bleeding. These organic substances are given topically to heavily exuding wounds to promote quick blood coagulation. Hemostatic agents are used to stop the blood flow, enhance hemostasis, and speed up clotting to speed up the coagulation process. These substances improve hemostasis by promoting primary hemostasis, promoting fibrin formation, or hindering fibrinolysis. Hemostasis is an essential component of all surgical procedures. Hemostatic drugs are increasingly in demand to prevent catastrophic blood loss due to a significant increase in the elderly population seeking treatment in numerous therapeutic disciplines. New hemostatic product launches and technological advances in the industry are also aiding the development of the category.
Bioresorbable, biocompatible, osteoinductive, osteoconductive, affordable, and simple to use are all characteristics of bone graft alternatives. They are frequently employed in spinal surgery, prosthesis reconstruction, traumatology, and oncological surgeries. Autografts are considered the gold standard in bone grafting, and allografts, in which patients use their bones, are common bone grafts. Compared to other allografts, allografts have a demineralized bone matrix that is more osteoinductive and osteoconductive. It is because of qualities like quick structural strength and osteoconductivity that allografts are increasingly being used instead of autografts. Allografts save time during surgery and hasten wound healing because no extra surgery is needed to remove the bone. As a result, bone grafts and replacements are frequently employed in various orthopedic surgery procedures.
The orthopedic issues brought on by weakening bones are expected to increase demand on a global scale. In the United States, QuickPack, a fully synthetic alternative to a bone graft that uses a high-viscosity calcium phosphate cement that closely resembles the mineral phase of natural bone, was introduced by OrthoPediatrics Corp., a business dedicated solely to developing the field of pediatric orthopedics. As a result, considering the aspects above, the category is anticipated to rise strongly over the forecast period.
Based on application, the global biosurgery market is bifurcated into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, and other applications.
The orthopedic surgery segment owns the highest market and is estimated to grow at a CAGR of 6.34% during the forecast period. The orthopedic market is predicted to proliferate, mainly as a result of increased geriatric populations and an increase in orthopedic procedures. The number of biosurgeries is rising due to benefits like cost-effectiveness, biocompatibility, bioresorbability, osteoconductive, and osteoinductive qualities of bio-surgical devices. The number of persons having joint replacement procedures, such as total hip and knee replacements, has risen significantly and is likely to keep rising as the population ages. The need for orthopedic procedures among people 65 and older is driven by increased musculoskeletal disorders and fractures linked to osteoporosis. Recent product introductions aid the segment's growth in the market. Altapore Shape Bioactive Bone Graft, which has received FDA approval, was introduced by Baxter International Inc. in May 2020. Therefore, the market under study is anticipated to experience a substantial CAGR over the forecast period, considering the rising incidences of arthritis and increasing bone-related ailments.
Current applications in cardiology include, among others, pacing leads, valve repair, shunts, reconstruction, vascular grafts, and atrial septal defects. Biosurgical devices are in demand for all these treatments due to their benefits. According to statistics, there has been an increase in the overall number of cardiac procedures, which is anticipated to fuel market expansion throughout the forecast period. Transfusion rates, hospital lengths of stay, and readmission rates significantly reduce when biological agents, including surgical sealants, adhesives, and soft tissue attachments, are used during cardiac surgical procedures, especially in high-risk operations. When supplementary measures are required, products like BD's Tridyne Vascular Sealant provide cardiovascular, cardiothoracic, and vascular surgeons with a novel, simple-to-use method to strengthen aortic anastomoses and control bleeding. These market products offer it a competitive edge. As a result, the significant growth of the market under study during the projected period is anticipated to be fueled by the increasing number of cardiac surgeries performed globally.
The global biosurgery market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor and is expected to grow at a CAGR of 5.64% during the forecast period. The United States Biosurgery Market is the largest regional market in the world. It is anticipated to increase over the forecast period due to the sharp rise in surgical procedures, the aging population's increased prevalence of chronic conditions, and the expansion of biosurgery-related research and development activities. The number of surgical procedures performed in the U.S. has risen significantly over the past ten years, according to the National Center for Biotechnology Information (NCBI), a trend anticipated to continue in the years to come. Due to the high mortality rate from heart disease, which makes it the second largest cause of death in Canada after cancer, more cardiac patients need surgical operations. Thus, increased surgical procedures will drive the demand for biosurgical products. The ceramic bone graft substitute Cerament G received approval from Health Canada and is the first injectable antibiotic-eluting bone graft substitute introduced on the Canadian market. Thus, the need for biosurgical products will develop throughout the projected period due to increased surgeries and rising public health awareness, leading to early diagnosis and treatment.
Europe is expected to grow at a CAGR of 7.25% during the forecast period. The market's growth in the United Kingdom is driven by the prevalence of diabetes and cardiovascular diseases, technological advancements, and the increasing focus of key players on R&D activities. Due to sedentary lifestyles, the prevalence of diabetes and cardiovascular diseases is increasing, which leads to wound-related complications during surgery, creating a positive demand for biosurgery products. Allograft bone has been widely used in the United Kingdom and is an attractive alternative as it avoids donor site morbidity. Osteoarthritic femoral heads removed at total hip replacement are the predominant source of allograft bone in the United Kingdom and remain the mainstay of grafts used in revision arthroplasty surgery.
In addition, Tissue Regenix Group has announced the launch of an operating division, "TRX BioSurgery." DermaPure, a decellularized, room-temperature stable dermal allograft, will be the flagship product under the TRX BioSurgery division. Currently commercialized under Tissue Regenix Wound Care, Inc., which will begin operating as ''TRX BioSurgery'', DermaPure has proven successful in multiple surgical applications. Hence, a rise in the adoption of new and advanced surgical products and the increasing number of surgeries in the market of the bio-surgical product helped in the overall growth of the biosurgery market. Biom’up announced the availability of its leading product, HEMOBLASTTM Bellows, in Spain. The Company has thus signed the first exclusive distribution agreement in Europe with Spain’s Palex Medical SA. Hence, it will likely impact the biosurgery products market as the number of surgical procedures increases during the forecast period.
China represents one of the significant healthcare industries in the Asia-Pacific region. The increasing pool of chronic disease patients and the rising number of surgical procedures are expected to significantly contribute to market growth. According to the National Bureau of Statistics of China, about 165,316 surgery procedures were registered in Qinghai Province, China. Japan accounts for one of the highest percentages of the older population. According to the World Ageing Population, in 2019, around 35,524,000 people in Japan were aged 65 years and above, and this number is expected to reach 39,882,000 by 2050. The elderly population will likely suffer from chronic diseases, driving the market's growth.
According to the Japan Society of Aesthetic Plastic Surgery, 231,457 facial and head procedures were performed in total in Japan in 2019. Body and extremities surgery are followed, with 11,623 performed that year. The market for biosurgery products is growing with the increase in aesthetic procedures. According to Arthritis-India, Osteoarthritis (OA) affects about 4-6% of the adult population and is mentioned as one of the top 5 chronic diseases in India and the country is likely to notice an endemic of osteoarthritis with about 80 percent of the 65 and above population in the country suffering with wear and tear of joints by 2025.
The Rest of the Middle East and African region includes Israel, Egypt, Iran, Syria, Jordan, Lebanon, and Nigeria. There is lower market penetration in these regions, owing to less focus on major companies in this region. The rising incidence of chronic diseases has strained the healthcare systems in the Middle East and Africa (MEA) region. Brazil has a higher mortality rate of road accidents than the other South American countries, approximately 20 per 100,000 individuals. In addition, the Brazilian Journal of Physical Therapy states that the incidence of sports injuries was 2.4/1000 hours in training and 42.8/1000 hours in matches. ANVISA (Agência Nacional de Vigilância Sanitária) is the Health Surveillance Agency that regulates the medical devices market in Brazil. A diverse environment for medical devices serves as an excellent platform for the bio-surgical products market growth. Hence, the same trend is expected to be followed, and the demand for biosurgery is expected to keep increasing. All these factors are expected to boost the market’s growth in the future.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|